

## CURRICULUM VITAE VALENTINA POLETTO

### Education

March 2015: PhD in molecular biology in Morpho-Pathology – University Federico II, Naples

16 September 2009: master degree in Medical Biotechnology - University of Pavia

23 July 2007: bachelor in Biotechnology – University of Pavia

### Research Experience

November 2009 – ongoing: contract as Biotechnologist at Center for the study of Myelofibrosis – S.C. Research and experimental laboratory, Biotechnology Area – IRCCS Policlinico San Matteo Foundation; Director: Dr. Vittorio Rosti.

My work is focused on the study of the molecular mechanisms involved in the pathogenesis of myeloproliferative neoplasms and on the study of the role played by Endothelial Progenitor Cells during angiogenesis in different solid tumors, focusing on the role played by Calcium signaling

### Technical skills and competences

*Molecular biology skills:* study of SNPs, gene expression in Real Time PCR and High resolution Melting; gene sequencing (Sanger); protein expression on cell lysates by Western Blotting; gene silencing with siRNA; Calcium imaging on Endothelial Progenitors Cells and on CD34+ cells; Calcium detection by fluorimetric analysis.

*Cellular biology skills:* ability in culturing Endothelial Progenitor Cells and Mesenchymal Stromal Cells; Matrigel assay; apoptosis study (Tunel Assay); migration assay after cell stimulation with specific growth factors.

### Selected publications

- *Dysregulation of VEGF-induced proangiogenic Ca(2+) oscillations in primary myelofibrosis-derived endothelial colony-forming cells.* Dragoni S, Reforgiato M, Zuccolo E, **Poletto V**, Lodola F, Ruffinatti FA, Bonetti E, Guerra G, Barosi G, Rosti V, Moccia F. *Exp Hematol.* 2015 Dec.
- *JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.* Catarsi P, Rosti V, Morreale G, **Poletto V**, Villani L, Bertorelli R, Pedrazzini M, Zorzetto M, Barosi G; AGIMM investigators. *PLoS One.* 2015 Jan 24
- *May the remodeling of the Ca2+ toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment?* Moccia F, Poletto V. *Biochim Biophys Acta.* 2014 Oct 31
- *Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms.* Avanzini MA, Bernardo ME, Novara F, Mantelli M, **Poletto V**, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V. *Leukemia.* 2014 Mar 12
- *Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis.* Dragoni S, Laforenza U, Bonetti E, Reforgiato M, **Poletto V**, Lodola F, Bottino C, Guido D, Rappa A, Pareek S, Tomasello M, Guarrera MR, Cinelli MP, Aronica A, Guerra G, Barosi G, Tanzi F, Rosti V, Moccia F. *PLoS One.* 2014 Mar 6;9(3):e91099
- *Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies.* Moccia F, Dragoni S, **Poletto V**, Rosti V, Tanzi F, Ganini C, Porta C. *Anticancer Agents Med Chem.* 2014 Feb;14(2):296-312.
- *No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.* **Poletto V**, Villani L, Catarsi P, Campanelli R, Massa M, Vannucchi AM, Rosti V, Barosi G. *Haematologica.* 2013 Aug;98(8):e83-4.
- *JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.* Barosi G, **Poletto V**, Massa M, Campanelli R, Villani L, Bonetti E, Viarengo G, Catarsi P, Klersy C, Rosti V. *PLoS One.* 2013;8(3):e59791
- *Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.* Rosti V, Villani L, Riboni R, **Poletto V**, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dallera E, Novara F, Massa M, Campanelli R, Fois G, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, Fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G. *Blood.* 2012 Nov 5.
- *A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.* **Poletto V**, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R, Massa M, Martinetti M, Viarengo G, Malovini A, Migliaccio AR, Barosi G. *Blood.* 2012 Oct 11;120(15):3112-7.
- *Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.* Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, Isgrò AM, Lupo L, Massa M, **Poletto V**, Viarengo G, Villani L, Magrini U. *PLoS One.* 2012;7(4):e35631